Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Optical coherence tomography, Pyrexia
Clinical narrative: ACUTE MACULAR NEURORETINOPATHY OF BOTH EYES (PERSISTENT CENTRAL SCOTOMATA IN BOTH EYES); CHILLS; FEVER; MYALGIA; HEADACHE; This spontaneous report was received from literature. This report concerned a 20 year old female of unknown enthnicity. The objective of the study was to report of ischemic retinal events occurring soon after administration of the covid-19 vaccine. The patient's height, and weight were not reported. The patient's concurrent conditions included: allergic rhinitis, and myopia, and other pre-existing medical conditions included: Patient had no known allergies. The patient denied any recent infections, trauma, and confirmed that she was not on any sympathomimetic agents. There was no family history of autoimmunity or coagulopathy. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported,1 total, administered on 12-APR-2021 for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. Concomitant medications included fluticasone for allergic rhinitis, and loratadine for allergic rhinitis and norgestimate-ethinyl estradiol. Patient discontinued birth control medication due to concern for thrombosis. On 13-APR-2021, the patient experienced chills, fever, myalgia, and headache. On 14-APR-2021, the patient experienced persistent central scotomata in both eyes. On an unspecified date, the patient was diagnosed with  acute macular neuroretinopathy of both eyes. Patient's visual acuity with correction was 20/20 in each eye, intraocular pressures were normal; pupils reacted briskly to light, and there was no relative afferent pupillary defect. Patient's peripheral visual fields were full to confrontation; however central visual field testing with Amsler grid revealed central defects in both eyes, extraocular movements of both eyes were intact, anterior segment examination was normal, with no evidence of inflammation. Dilated fundus examination was normal; there were no clinically observable ocular findings to explain visual symptoms. MRI brain showed acute abnormalities, Optical coherence tomography showed a trace perfusion defect in the deep capillary plexus of the left eye and slight alteration of the foveal avascular zone in both eyes, and Optical coherence tomography demonstrated corresponding ellipsoid zone disruption. Treatment medications (dates unspecified) included: ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from fever, chills, myalgia, and headache, and the outcome of acute macular neuroretinopathy of both eyes (persistent central scotomata in both eyes) was not reported. The authors emphasized on potential side effects of COVID-19 vaccines. It was postulated that the patient, their immunologic responses to the vaccines and possibly a resultant pro thrombotic state may have precipitated their ischemic retinal events. It was recommended that patients with ocular symptoms after COVID-19 vaccination undergo comprehensive ophthalmologic evaluation. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20220452135-Covid-19 vaccine ad26.cov2.s-Acute macular neuroretinopathy of both eyes. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). Therefore, this event(s) is considered unassessable.